Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Nawroth

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Der Urologe. Ausg. A|September 9, 2016
[Modern networks : Topics in the working group "Bladder cancer research" of the GeSRU Academics]S Hofbauer, C Kalogirou, F Roghmann, et al.
Der Urologe. Ausg. A|January 20, 2011
[Bladder cancer update: what was new at the 2010 annual congress of the German Association of Urology in Düsseldorf?]R Nawroth, A Hartmann, P J Olbert, et al.
British Journal of Cancer|October 29, 2014
Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapyA Sathe, F Guerth, M V Cronauer, et al.
Der Urologe. Ausg. A|January 30, 2013
[Bladder cancer in focus: update 2012 of the German Bladder Cancer Association]B Keck, A S Merseburger, R Stöhr, et al.
Journal of Cancer Research and Clinical Oncology|February 25, 2015
Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapyM Thalgott, M M Heck, M Eiber, et al.
Nuklearmedizin. Nuclear Medicine|February 12, 2013
[[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model]S Schwarzenböck, D Sachs, M Souvatzoglou, et al.
World Journal of Urology|June 10, 2015
The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancerT Horn, J Laus, A K Seitz, et al.
Urologic Oncology|October 20, 2022
Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part IIIM J Reike, M A Ingersoll, D C Müller, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Der Urologe. Ausg. A|September 9, 2016
[Modern networks : Topics in the working group "Bladder cancer research" of the GeSRU Academics]S Hofbauer, C Kalogirou, F Roghmann, et al.
Der Urologe. Ausg. A|January 20, 2011
[Bladder cancer update: what was new at the 2010 annual congress of the German Association of Urology in Düsseldorf?]R Nawroth, A Hartmann, P J Olbert, et al.
British Journal of Cancer|October 29, 2014
Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapyA Sathe, F Guerth, M V Cronauer, et al.
Der Urologe. Ausg. A|January 30, 2013
[Bladder cancer in focus: update 2012 of the German Bladder Cancer Association]B Keck, A S Merseburger, R Stöhr, et al.
Journal of Cancer Research and Clinical Oncology|February 25, 2015
Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapyM Thalgott, M M Heck, M Eiber, et al.
Nuklearmedizin. Nuclear Medicine|February 12, 2013
[[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model]S Schwarzenböck, D Sachs, M Souvatzoglou, et al.
World Journal of Urology|June 10, 2015
The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancerT Horn, J Laus, A K Seitz, et al.
Urologic Oncology|October 20, 2022
Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part IIIM J Reike, M A Ingersoll, D C Müller, et al.
Pageof 3